CRISPR Therapeutics AG is a long-term buy despite slow Casgevy uptake. Click for my updated look at CRSP earnings and the ...

CRISPR Therapeutics (SRSP) stock gains as the company gets a new Overweight rating from J.P. Morgan thanks to its therapeutic ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best emerging technology stocks to buy right now. On September 3, Bank of ...

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $59.07, marking a -3.46% move from the previous day.

Crispr Therapeutics AG ( ($CRSP) ) has risen by 7.75%. Read on to learn why. Crispr Therapeutics AG has experienced a notable 7.75% increase in ...

While the telephone brought comfort, smartphones changed lives. While factories powered economies, artificial intelligence ...

What you need to know about Ark Invest, an active ETF firm led by Cathie Wood that invests in disruptive, high-growth tech ...

Analysts are intrested in these 5 stocks: ( ($DECK) ), ( ($CRDO) ), ( ($CRSP) ), ( ($AVAV) ) and ( ($ANF) ). Here is a breakdown of their recent ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Splitting shares won't double your money. When a stock splits, shareholders each get more shares. The price per share falls proportionally.

In addition to CRSP, ARK also made a substantial investment in Beam Therapeutics Inc (NASDAQ:BEAM), buying 491,127 shares through the ARKK ETF, amounting to over $11.2 million. This purchase aligns ...